Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W. Beheshti M, et al. Among authors: kahkonen e. Eur Radiol. 2023 Jan;33(1):472-482. doi: 10.1007/s00330-022-08982-2. Epub 2022 Jul 21. Eur Radiol. 2023. PMID: 35864350 Free PMC article. Clinical Trial.
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. Kähkönen E, et al. Clin Cancer Res. 2013 Oct 1;19(19):5434-43. doi: 10.1158/1078-0432.CCR-12-3490. Epub 2013 Aug 9. Clin Cancer Res. 2013. PMID: 23935037 Free article.
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H. Jambor I, et al. Among authors: kahkonen e. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29147764 Clinical Trial.
Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.
Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Movahedi P, et al. Among authors: kahkonen e. Sci Rep. 2020 Jun 10;10(1):9407. doi: 10.1038/s41598-020-66255-8. Sci Rep. 2020. PMID: 32523075 Free PMC article. Clinical Trial.
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Jambor I, et al. Among authors: kahkonen e. J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6. J Magn Reson Imaging. 2017. PMID: 28165653
Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
Falagario U, Jambor I, Taimen P, Syvänen KT, Kähkönen E, Merisaari H, Montoya Perez I, Knaapila J, Steiner A, Verho J, Tewari A, Aronen HJ, Carrieri G, Boström PJ, Ettala O. Falagario U, et al. Among authors: kahkonen e. World J Urol. 2021 Jun;39(6):1879-1887. doi: 10.1007/s00345-020-03393-8. Epub 2020 Aug 10. World J Urol. 2021. PMID: 32778912 Free PMC article.
IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.
Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P. Merisaari H, et al. Among authors: kahkonen e. J Magn Reson Imaging. 2019 Nov;50(5):1641-1650. doi: 10.1002/jmri.26727. Epub 2019 Mar 22. J Magn Reson Imaging. 2019. PMID: 30903647
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ. Jambor I, et al. Among authors: kahkonen e. PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun. PLoS Med. 2019. PMID: 31158230 Free PMC article. Clinical Trial.
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men.
Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtiö K, Rantala T, Rottmann A, Sipilä H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H. Roivainen A, et al. Among authors: kahkonen e. J Nucl Med. 2013 Jun;54(6):867-72. doi: 10.2967/jnumed.112.114082. Epub 2013 Apr 5. J Nucl Med. 2013. PMID: 23564761 Free article. Clinical Trial.
34 results